PRNewsWire
12 Aug 2026, 10:50 UTC · 1h ago
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
12 Aug 2026, 10:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
BD has completed enrollment for the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias. — Successful enrollment is a critical milestone toward gaining FDA approval for a product targeting a significant unmet medical need, potentially opening a new revenue stream.
+0.40Data from the PREVENT trial will be used to support a planned submission to the U.S. Food and Drug Administration (FDA) for this specific indication. — Regulatory submission is the primary catalyst for commercialization, though the ultimate impact depends on the trial's efficacy results.
+0.30The PREVENT study is the first large-scale randomized study to evaluate prophylactic reinforcement using a resorbable mesh for incisional hernia prevention. — Establishing a first-mover advantage in a new clinical application provides a competitive edge in the medical technology market.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company successfully completed enrollment in a large-scale clinical trial for its Phasix Mesh, moving it closer to FDA submission.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
32m ago
